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1. Introduction
MicroRNAs (miRNAs) are a recently discovered class of endogenously expressed, single
stranded, non-protein coding RNAs of about 19-25 nucleotides in length, that bind to the 3`
un-translated regions (UTR) of target messenger RNAs (mRNAs) through complementarity
with the first 2-8 nucleotides at the 5` end of the miRNA. They play important roles in diverse
biological and pathological processes, through the regulation of gene expression at both
transcriptional and post-transcriptional level [1,2]. The miRNA-mediated gene regulation is
part of a larger mechanism known as RNA interference which involves other regulatory RNAs;
small interfering RNAs (siRNA), which induce silencing of specific mRNA through comple‐
mentary nucleotide sequences, and piwi-interfering RNAs (piRNAs) which, through similar
mechanisms, induce silencing of active mobile elements to maintain germ line integrity and
fertility. To date, over 1000 miRNAs and 16,228,619 predicted mRNA target sites have been
identified, affecting over 30% of the human genome [3]. What makes them important players
in regulating protein expression is the ability of a single miRNA to interact with more than
one target gene (due to the imperfect matching between miRNA and its target which still
produces a functional effect). In addition, a single gene can be regulated by multiple miRNAs.
Currently, around 200 human transcription factor-miRNA relationships have been described
and collated into the TransmiR database [4]. These include transcription factors such as Nanog
and Oct3/4, [5], hormones such as estradiol [6], and tumor suppressor genes such as p53 [7].
Since the initial reports of the miRNAs lin-4 and let-7 as developmental regulators of Caeno‐
rhabditis elegans (C. elegans) [8,9], there have been numerous studies describing the involvement
of miRNAs in normal cellular function as well as in various disease conditions, such as cardiac
arrhythmias [10,11], fibrosis [12,13], remodeling [14,15], metabolic disorders [16], diabetes [17],
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Alzheimer and Parkinson`s disease [18], autoimmune disorders (e.g. systemic lupus eryth‐
ematous, rheumatoid arthritis and multiple sclerosis) [19], stroke [20] and schizophrenia [21].
This chapter will summarise and discuss recent evidence elucidating the role of these newly
discovered regulators of gene expression in cancer pathogenesis, with particular emphasis on
breast cancer.
1.1. Biogenesis of miRNAs
The biogenesis of mature miRNA is a multistep process which requires the contribution of
various enzymes, binding proteins and transporters. In the nucleus, miRNAs are transcribed
from either intra-or inter-genic regions by RNA polymerase II to form the primary miRNAs
(pri-miRNAs), structures of approximately 1-3 kb in length [22]. These are initially cleaved by
RNase III enzyme Drosha, and the double-stranded RNA-binding partner protein Pasha
(DiGeorge Syndrome Critical Region 8 Protein), into stem-loop structures of approximately
50-70 nucleotides, with a 3` overhang of a few nucleotides, termed precursor-miRNAs (pre-
miRNAs) [23,24]. These pre-miRNAs are then transported into the cytoplasm by a nuclear
exporter protein termed Exportin-5 (RanGTP-dependent dsRNA-binding protein) [25]. Once
in the cytoplasm, the pre-miRNAs are further cleaved from their terminal loops into double-
stranded oligonucleotides of approximately 18-24 bp in length into mature miRNA, by RNase-
III Dicer: miRNA* duplexes [26]. These strands are then separated and one of them becomes
a mature miRNA molecule to be incorporated with several argonaute (AGO) and other
proteins into an RNA-induced silencing complex (RISC) which either perfectly or imperfectly
hybridises with its target mRNA. In case of near-perfect to perfect matching, this results in
mRNA cleavage and degradation by the action of mRNA processing bodies [27,28,29,30], while
translational inhibition or sequestration of mRNA from the translational machinery results in
the case of imperfect matching [27,31]. In either event, the end result is ultimately reduced
protein levels. In vertebrates, most of the miRNA-mRNA interactions are of imperfect
complementarity at the 5` end seed sequence [32], unlike the plant miRNA-mRNA interactions
which generally target via perfect complementarity [33]. It has been suggested that the miRNA
star strand is often degraded, but some evidence suggests that it plays a role in the regulation
of miRNA homeostasis and other downstream effects [34,35]. For example, ectopic expression
of miRNA-24-2 star strand in the estrogen receptor (ER) positive breast cancer cell line MCF-7,
results in suppression of cell survival, through the targeted suppression of protein kinase Cα
(PKCα), and decreased tumor formation when injected into nude mice [36]. Recent evidence
suggests the existence of alternative miRNA biogenesis pathways not involving Drosha
activity, from introns that bear hairpin structures similar to Drosha processed pre-miRNAs.
These miRNAs are termed mitrons [37,38,39]. Both pathways merge at the point of cytoplasmic
transfer via Exportin-5. In addition, another new group of miRNAs (termed smitrons) has been
described as splicing-independent mitron-like miRNA, which require Drosha activity but not
splicing, DGCR8 or Dicer activity [40,41,42,43]. Their subsequent mechanism of processing
into the RISC is unclear. These events are illustrated in Figure 1.
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Figure 1. miRNA biogenesis. Following transcription by RNA polymerase II from intergenic, intronic or polycistronic
regions, the primary transcripts (pri-miRNA) are processed by drosha/DGCR8 enzyme complex into approximately 70
nucleotide pre-miRNA hairpin structures. Two other pathways involving short intronic hairpins have been described;
mirtrons that are spliced and processed via a debranching enzyme (DRB1), and simtrons that are processed by drosha
in cooperation with an unknown factor. All enter the cytoplasm through Exportin-5/RAN-GTP activity (except for the
simtron-derived molecule which is processed by other undefined mechanisms) and are further processed by dicer/
TRBP into a duplex form which then associates into an RNA induced silencing complex (RISC). Within this, RNase H
activity degrades the passenger strand and the antisense strand guides the complex to its target mRNA sequence in the
3’ UTR sequence downstream of the open reading frame (ORF). Perfect base pairing results in mRNA degradation,
and permitted imperfect matching, in mRNA de-stabilisation, both of which result in translational blockade.
1.2. Physiological role of miRNAs
Aside from their major function of inducing mRNA target gene degradation or translational
inhibition, several specific actions of miRNAs have been reported. One such is in senescence-
associated transcriptional gene silencing; an event triggered by cancer-initiating or promoting
events, through repression of proliferation promoting genes regulated by a retinoblastoma
protein (RB)/E2F repressor complex. For example, AGO2, RB1 and let-7 interact to repress RB1/
E2F-target genes in senescence in premalignant cancer cell lines, which may contribute to
tumor suppression [44]. In addition, miRNA can positively regulate gene expression by
targeting promoter elements of protein coding genes, a phenomenon known as RNA activation
(RNAa). For example, transfection of miRNA-373 and its precursor (pre-miRNA-373) into the
prostate cancer cell line PC-3, resulted in the induction of E-cadherin and cold-shock domain-
containing protein C2 (CSDC2) expression [45]. Also, miRNA-744,-1186 and-466d-3p can
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induce the expression of cyclin B1 in mouse cell lines and lead to chromosomal instability and
tumor suppression in vivo [46].
A diverse range of biological processes appear to be at least partly regulated by miRNAs. These
include early development and developmental timing [47,48], hematopoietic lineage differ‐
entiation [49], cellular differentiation, proliferation and apoptosis [50,51,52], development and
function of innate [53,54,55,56] and adaptive [57,58,59,60] immune response, neurotransmitter
synthesis [61], viral replication [62], insulin secretion [63] and cardiac rhythm [64].
1.2.1. Development
Genetic  deletion  studies  indicate  that  some  developmental  processes  are  absolutely
dependent on miRNAs. In C. elegans, miRNAs play a role in locomotion, body size and egg
laying [65].  For  example,  lin-4  and let-7  control  the  timing of  larva  development  [8,66];
severe defects in germline development and embryonic morphogenesis was evident in dcr-1
mutant  worms  [67].  In  Drosophila,  cell  division  defects  were  evident  in  dicer-1  mutant
germline stem cells, with marked reduction in the rate of germline cyst production and cell
cycle control (delayed G1 to S transition) [68].  Mice null  in Direc-1 and AGO-2, did not
survive  beyond embryonic  day (ED)  7.5  [69].  Some miRNAs show temporal  expression
profiles during mouse prenatal development (at ED 9.5, 10.5 and 11.5); miRNA-2 and-193
showed specific expression in mouse embryo at ED 10.5 suggesting a role in developmen‐
tal transitions [70]. In human embryonic stem cells, about 14 miRNAs were found to interact
with  developmental  transcription  factors  such as  POU class  5  homeobox 1  (OCT4),  sex
determining region Y (SRY)-Box 2 (SOX2),  and Nanog Homeobox (NANOG) [70].  Some
miRNAs, such as 142 and 181, were shown to be specifically expressed in hematopoietic
tissues, suggesting a role in morphogenesis [71], while Dicer and AGO gene family (mainly
AGO-1 and 2) transcripts were restrictively expressed at ED 11.5 and 14.5 in specific organs
including brain, neural tube, limb, lungs and hair follicles, with significant expression in
lung  tissues  undergoing  branching  morphogenesis  [72].  Dicer-1  deficient  mouse  lungs
exhibit defective morphology, with significant apoptosis in the epithelium [73].
Involvement of miRNAs in the development of the cardiovascular system [74] is reflected by
variable expression/activity of miRNAs such as-126,-143,-145, and-218 [75]. miRNA-1 has a
unique expression profile in cardiac myocytes and plays a critical role in heart development,
by influencing cardiac morphogenesis, electrical conduction and cell-cycle control [76]. It is
strongly expressed during heart development between ED 8.5-11.5 and represses the expres‐
sion of heart and neural crest derivatives expressed-2 (Hand-2) transcription factors, which
are responsible for ventricular cardiomyocyte differentiation [77]. In the nervous system, Dicer
deficient zebra fish show defects in neuronal cell differentiation and development [78]. In
mammals, miRNA-124 and-128 are highly expressed in neuronal progenitor cells and mature
neurons, and are considered to be the main regulators of neuronal development [79,80,81].
miRNA-124a is thought to constitute 25-50% of the total brain miRNA population, and is
implicated in switching brain progenitor cells into a neuron lineage [82]. miRNA-134 plays a
role in central synaptic function [83,84]. miRNAs are also implicated in the development of
skeletal muscles; miRNA-1 is abundantly expressed in the muscle progenitor cells and
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differentiating muscle [77], and facilitates myotube formation [85] by interacting with muscle
differentiating factors such as serum response factor (SRF), myocyte enhancer factor-2 (MEF-2)
and myogenic regulatory factors (MRFs) [77].
1.2.2. Differentiation
miRNAs have been shown to play an important role in the differentiation of pluripotent
embryonic stem (ES) cells which gives rise to more than 200 cell types in the adult body.
Differential expression has been observed during ES cell differentiation, with decrease in
miRNA 290-295 cluster and-296, and increase in miRNA-21 and-22 [86]. Mice oocytes with
targeted deletion of Dicer, failed to produce any miRNA, resulting in failure of cell division,
in part due to disorganized spindle formation, reflecting the importance of maternal miRNAs
in the earliest stages of embryonic development [87]. Over-expression of miRNAs 290-295/302
could overcome the proliferation defects of Dgcr8 mutant mouse ES cells, whereas over-
expression of Let-7 could rescue them from their differentiation defects [79]. Reduced expres‐
sion of Let-7 was seen in breast tumor initiating cells (BT-IC), and its forced expression
markedly reduced BT-IC proliferation and the proportion of undifferentiated cells, with
subsequent reduction in tumor size and metastasis through reduced expression of its targets,
H-RAS and HMGA2 [88].
2. Involvement of miRNAs in etiology of cancer
Numerous miRNAs are involved in controlling the activity of intracellular signaling molecules
(e.g. MAPK, PI3K/PTEN, NFκB, TGFβ, Notch, and Hedgehog) which are critical in regulating
multiple processes linked to cancer pathogenesis such as proliferation, apoptosis, angiogenesis
and immune function, emphasizing their potential value in cancer classification, as diagnostic
biomarkers for staging, predictive markers of prognosis and response to therapy, and as
therapeutic targets [89,90,91]. For example, miRNA-21 is described as a positive-feedback
regulator of MAPK/ERK1/2 pathways. Its own expression is induced by the activation of
ERK1/2, whose activity it then increases by repressing negative regulators of ERK/MAPK.
Stimulation of HER2/neu signaling enhances MAPK/ERK phosphorylation, which results in
enhanced miRNA-21 levels and increased invasive capacity of HER2/neu expressing breast
cancer cells, by repression of the metastasis suppressor protein; programmed cell death 4
(PDCD4) [92]. The miRNA-200 family have been reported to target the downstream mediators
of the TGF-β pathway, ZEB-1 and-2, resulting in inhibition of the epithelial to mesenchymal
transition process (EMT), with subsequent suppression of metastasis in various cancer cell
lines including those of the breast [93,94]. Interestingly, ZEB1 reduces the expression of the
miRNA-200 cluster and hence promotes EMT in a feed-forward manner [95]. Let-7 directly
targets the Ras proto-oncogene which plays a major role in cancer pathogenesis [96]. Phos‐
phatase and tensin homolog (PTEN), considered one of the main negative regulators of the
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway, is targeted by various
miRNAs including miRNA-21,-26a,-221, and-222 [90]. miRNA-21 enhances proliferation,
survival and migration in cancer cells through targeting of PTEN, leading to enhanced PI3K
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activity [97]. The role of the transcription factor, NFκB, is well established in cancer patho‐
genesis, and some evidence suggests that several miRNAs, such as-301,-146,-155, and-9,
indirectly activate it by inhibiting the NFκB repressing factor (NKRF) [98,99].
A multiplicity of factors, that include chromosomal instability, genomic mutations and
polymorphisms, epigenetic changes, alterations in synthetic pathways, promoter methylation,
or changes in the activity of their transcriptional factors, modify the expression of miRNAs
[29,86]. For example, single nucleotide polymorphism (SNP) type mutations in miRNA-146a
can predispose for development of various tumors [100,101,102] including those of the breast
[103]. Specific G/C polymorphisms (rs2910164) in miRNA-146a precursor leads to increased
production of the mature form, which binds to and modulates the BRCA1 and BRCA2 genes,
whose activity is a predisposing factor for early onset familial breast cancer [103].
Although miRNAs have been found to be both over-as well as under-expressed in cancer cells
as compared with normal tissues, the more frequent observation is one of decreased expres‐
sion. For example, whereas miRNA-21 is elevated, miRNAs-126,-143, and-145 are all decreased
in most (~ 80%) types of tumors [104]. This means that miRNAs can function both as oncogenes
(e.g.-9,-17-92 cluster,-21,-27a,-103,-106,-107,-125b, and-155) or more often, as tumor suppressor
genes (e.g. let-7,-15a, 16-1, 23b, 29a/b/c, 34a, 124, 133, 137, 143, 145, 192, and 215)
[102,105,106,107,108,109,110,111].
Analysis of dysregulated miRNA expression may also have prognostic relevance in many
cancers; for example, metastatic breast tumors show elevated miRNA-10b and reduced
miRNA-126,-206, and-335 levels [112,113]. A recent report suggested that higher expression of
miRNA-126 and-10a in breast cancer patients was associated with longer relapse-free survival
[114]. The detection of circulating miRNA in plasma and serum also presents these molecules
as potential novel biomarkers for cancer and other diseases. A pilot study showed that
miRNA-155 serum levels could be a significant index to distinguish patients with breast cancer
from healthy individuals, and serum levels of miRNA-34 could indicate disease prognosis
[115]. Another report [116] suggested that four miRNAs,-215,-299-5p,-411, and-452, that were
differentially expressed between serum samples from patients with metastatic breast cancer
and healthy volunteers, could be used as biomarkers for detection and staging; requiring only
a blood sample. Heneghan et al [117] demonstrated increased serum levels of miRNA-195 in
breast cancer patients (as compared with healthy control subjects), which were then decreased
(together with let-7a) after curative tumor resection. Molecular classification of non-BRCA1/2
hereditary breast tumors into four distinct subgroups, on the basis of their miRNA expression
profiles, was used in a recent report to search for novel susceptibility pathways in hereditary
breast cancer [118]. Furthermore, high expression of let-7, miRNAs-21,-23, and-27a has been
linked with drug resistance in ovarian cancer [119]. miRNA-452 was shown to be significantly
down-regulated in adriamycin-resistant, as compared with the parental MCF-7 breast cancer
cells; modulating its level partially reversed the adriamycin-resistance, by targeting insulin-
like growth factor-1 receptor (IGF-1R) [120].
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3. Role of miRNAs in EMT
3.1. Pathways of the EMT process
Cellular transition from epithelial to mesenchymal phenotype (EMT) and vice versa (MET) was
first identified as a physiological event occurring during embryonic development [121].
Currently, it is well established that the EMT process is a hallmark event occurring in a number
of disease conditions including breast cancer [122]. In our laboratory, it has been demonstrated
that EMT can be induced in breast cells in vitro, in parallel with development of endocrine
resistance induced by blockade of ERα function, and this results in enhanced cellular prolif‐
erative and invasive capacity [123,124]. During the EMT process in vivo, individual epithelial
cells lose their cell-cell and cell-matrix contacts and apico-basolateral polarity, and gain a
mesenchymal phenotype which enables them to dissociate from the tumour mass, invade into
and interact with the extracellular matrix (ECM) before entering blood and lymphatic vessels.
Many phenotypic changes occur during this process; these include loss of cell-cell adhesion as
a result of reduced E-cadherin and catenins expression in adherens junctions, reduced claudins
and occludins expression at tight junctions and reduced expression of various epithelial
cytokeratins such as KRT8, 18 and 19, which presumably aids in disruption of cytoskeletal
connections that maintain tissue architecture [123]. Various transcription factors such as WNT,
NOTCH, TWIST, ZEB1/TCF8, ZEB2, SNAIL, SLUG, GOOSECOID, FOXC1/2, E12/E47 and
TCF3, and downstream mediators of several growth factor receptors such as TGFβ, IGF1R,
epidermal growth factor receptor (EGFR), platelet derived growth factor receptor (PDGFR),
fibroblast growth factor receptor (FGFR), and signaling molecules PI3K/AKT, mTOR, ERK/
MEK, and MAPK all play important roles in the EMT process, which has been described in
detail previously [122,123,125]. In addition, the stroma of neoplastic tissues and hypoxia can
also induce EMT through the production of hypoxia induced factor (HIF-1α) [123].
3.2. miRNAs implicated in the EMT process in breast cancer
miRNA can either induce or inhibit the EMT process by modulating various target genes
(Figure 2)
3.2.1. Inducers of EMT
miRNA-9: miRNA-9 is up-regulated in breast cancers relative to normal tissues [126]. It
showed a thousand-fold increase seen in c-myc-induced mouse mammary tumours [127], and
its level was significantly elevated in primary breast tumours from patients with diagnosed
metastases, in comparison with those from metastasis-free patients [128]. This is consistent
with its higher expression in HER2+and triple-negative (ERα-ve/progesterone receptor (PR)-
ve and HER2-ve) tumours, in comparison to luminal subtypes, and in tumours with advanced
T stage, high histologic grade, p53 over-expression and high proliferation index, as well as in
tumors with mesenchymal-like phenotype (high vimentin, low E-cadherin) [129]. Ectopic
expression of miRNA-9 leads to an EMT-like conversion in human mammary epithelial cells
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in vitro. These become scattered with spindle-like morphology and exhibit a significant
decrease in E-cadherin and increase in vimentin [128].
miRNA-24: TGF-β acts both as a tumor suppressor in early-stage adenomas, through its ability
to inhibit cell growth and, as an important promoter of the EMT process during late stages of
cancer progression [130]. Expression of miRNA-24 was significantly increased in breast cancer
cell lines which had undergone TGF-β-induced EMT through targeting the guanine nucleotide
exchange factor Net1A; an important activator of Rho kinase [131,132]. In addition, Papadi‐
mitriou et al [131] showed that miRNA-24 levels are up-regulated in metastatic compared with
primary breast tumor samples with mesenchymal phenotype.
miRNA-29: N-myc interactor (NMI) is a cytokine-inducible protein that interacts with several
transcription factors important in tumour progression such as STATs, myc, BRCA1, TIP60 and
SOX10 [133,134], and loss of NMI expression promotes EMT by the activation of TGFβ
signaling pathway [135]. A recent report by Rostas et al [136] showed increased levels of
miRNA-29 in the highly invasive mesenchymal-like breast cancer cell lines, and its over-
expression in breast cancer cells expressing robust level of NMI resulted in decreased NMI
expression and increased invasion, whereas treating cells with miRNA-29 antagonist increased
NMI expression, reversed EMT, and decreased invasion, suggesting a novel inverse regulatory
relationship of NMI and miRNA-29 in breast cancer.
miRNA-29a: enhanced miRNA-29a and reduced tristetraprolin (TTP, a protein involved in the
degradation of mRNAs with AU-rich 3' UTRs) was observed in breast cancer patient samples
with invasive phenotype. Over-expression of miRNA-29a induced EMT and metastasis in Ras-
transformed mouse mammary epithelial cells through suppression of TTP [137].
miRNA-103/107: enhanced miRNA-103/107, and reduced expression of the RNase III endo‐
nuclease Dicer, was observed in breast cancer cell lines with highly invasive mesenchymal
phenotype. Over-expression of miRNA103/107 induced Dicer down-regulation and induction
of EMT, with subsequent enhancement in invasive capacity. Furthermore, miRNA103/107
could induce EMT by decreasing miRNA-200 (which negatively regulates EMT), and control‐
ling the levels of ZEB1/2 in a miRNA-200-dependent manner [138,139].
miRNA-106b-25 cluster: the expression profile of this miRNA cluster in human breast cancer
patients significantly correlates with metastatic phenotype and shorter relapse free survival.
Over-expression induced EMT in breast cancer cell lines, with reduced E-cadherin and
increased expression of mesenchymal markers such as β-catenin, Jag1, MMP-9 and vimentin,
as well as increasing the percentage of cells with tumor initiating characteristics (CD24low
CD44+); typical of mesenchymal cells. This cluster also induced EMT by enhancing the action
of the metastatic regulator Six1 (a major mediator of the TGF-β-initiated EMT promoting
pathway) and by targeting the inhibitory Smad7 protein, which results in increased levels of
the TGF-β type I receptor and downstream activation of TGF-β signaling [140].
miRNA-155: Johansson et al [141] have demonstrated that miRNA-155 could mediate a switch
in TGFβ effect, from tumor suppression to induction of EMT both, in breast cancer cell lines,
and in MMTV-PyMT mice. Treatment of mouse mammary gland epithelial cells with a
synthetic miRNA-155 mimic repressed the level of the mammary epithelium differentiation
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factor CCAAT-enhancer binding protein beta (C/EBPβ) and induced EMT in response to
TGFβ treatment; loss of E-cadherin expression, induction of vimentin, and enhanced meta‐
stasis and invasion, both in vitro and in vivo.
miRNA 221/222: miRNA-221/222 induces EMT and subsequent enhancement in invasion by
decreasing expression of epithelial-specific genes while increasing expression of mesenchy‐
mal-specific genes, in part through stimulation of the transcription factor FOSL1 (Fra-1) and
reduction of adiponectin receptor 1 (ADIPOR1). miRNA-221/222-mediated reduction of E-
cadherin was effected through targeting of the 3' UTR of the GATA family transcriptional
repressor TRPS1 (tricho-rhino-phalangeal syndrome type 1), and modulating ZEB2 levels
[142,143,144]. Lambertini et al [145] showed that miRNA-221can induce EMT in MDA-MB-231
cells by directly targeting SLUG, a master regulator of the EMT process. Another recent report
showed that the secreted form of miRNA221/222 serves as a signaling molecule which plays
a pivotal role in the induction of tamoxifen resistance in the ER+ve breast cancer cell line
MCF-7; this can be blocked by anti-miR221/222 treatment [146].
Figure 2. Regulation of EMT in breast cancer cells. miRNAs can act as either inducers or inhibitors of EMT by in‐
creasing (blue) or decreasing (red) the expression of various target genes as indicated.
3.2.2. Inhibitors of EMT
miRNA-7: Zhang et al [147] showed that miRNA-7 expression was significantly reduced in
cancer stem cells isolated from MDA-MB-231 and MCF-7 cell lines, and down-regulates the
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oncogene SETDB1 by targeting the 3`UTR of the mRNA. Over-expression of miRNA‐7
suppressed the EMT‐like characteristics of MDA-MB‐231 cells, as reflected in the observation
that these cells became less scattered and lost their spindle‐like morphology, increased E-
cadherin and reduced vimentin expression. This was in part due to reduced expression and
activity of STAT3.
miRNA-124: as mentioned previously, this miRNA is highly expressed in the brain and plays
a crucial role in neural development. Recent evidence suggests that it is also involved in cancer
pathogenesis, with reduced expression seen in various cancers, including the breast. Its
expression was inversely correlated to histological grade. Its over-expression could repress
many of the mesenchymal characteristics of highly metastatic breast cancer cell lines (e.g.
MDA-MB-231 and B-549) [148] by reducing SLUG expression, through direct interaction with
its 3′-UTR region.
miRNA-145: Hu et al [149] have demonstrated that the expression of miRNA-145 was de‐
creased in breast tumor tissues with invasive phenotype, and its over-expression in various
breast cancer cell lines leads to enhanced E-cadherin expression, reduced expression of
fibronectin, ZEB1/2 and SNAIL, and inhibition of EMT by targeting Oct4.
miRNA-200 family and miRNA-205: expression of the miRNA-200 family (miR‐
NA-200a,-200b,-200c,-141 and-429) and miRNA-205 were found to be significantly reduced in
breast cancer cell lines with mesenchymal phenotype, but high in E-cadherin expressing cells
with epithelial characteristics. Similarly, their expression was lost in regions of metaplastic
breast tumours with mesenchymal characteristics and lacking E-cadherin expression [94].
Enforced expression of miRNA-200 alone was sufficient to prevent EMT induced by TGFβ
stimulation [94]. ZEB-1 (TCF8/deltaEF1) and ZEB-2 (SMAD-interacting protein 1 [SIP1]/
ZFXH1B), which are able to initiate EMT by binding to E-boxes within the E-cadherin pro‐
moter, repressing its transcription, were the main target genes for these miRNAs [150]. Over-
expression of miRNA-200 could induce MET in both normal and cancer cell lines and reduce
the motility and invasiveness of MDA-MB-231 by enhancing E-cadherin expression [151,152].
Chen et al [153] demonstrated that the loss of miRNA-200c in breast cancer cells was correlated
with both EMT and acquired resistance to doxorubicin. In addition, decreased levels of E-
cadherin and PTEN, and increased levels of ZEB1 and phospho-Akt were seen in these cells,
which correlated with loss of miRNA-200c. Ectopic expression of miRNA-200c reversed all of
these changes, suggesting that miRNA-200c inhibits the acquired resistance of breast cancer
cells against doxorubicin through inactivation of the PI3K/Akt signaling pathway.
miRNA-375: this was reported to be significantly down-regulated in tamoxifen-resistant
(TamR) MCF-7 cells which had acquired a mesenchymal phenotype. Its re-expression re-
sensitized the TamR cells to tamoxifen, reversed the EMT process, and reduced invasiveness
by targeting the metadherin (MTDH) gene [154].
miRNA-448: suppression of miRNA-448 induced EMT in MCF7 cells, with characteristic
acquisition of a fibroblast-like cell morphology, dissolution of tight junctions (ZO-1), formation
of F-actin stress fibers, severe E-cadherin suppression and enhanced vimentin expression. In
addition, enhanced invasive capacity was also observed upon miRNA-448 inhibition in vitro.
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These effects were due to direct targeting of specific AT-rich sequence-binding protein-1
(SATB1) mRNA, leading to elevated levels of amphiregulin and EGFR-mediated TWIST1
expression, as well as NF-κB activation through the MAPK and PI3K/Akt pathways. On the
other hand, over-expression of miRNA-448 in MDA-MB-231 cells (which otherwise express
very low levels), leads to MET and decreases cell migration and invasion. Similar effects were
also observed in vivo where miRNA-448-silenced MCF-7 cells (which are usually poorly
invasive) showed a spindle-like morphology, with islands of cancer cells that had invaded the
muscle and lung tissues when injected into the left flank of nude mice [155].
3.2.3. Role of p53 in EMT and miRNA expression
Deletions and/or mutations in p53 are frequently involved in the pathogenesis of many human
cancers including those of the breast (mutated in 25-30% of breast cancers) [156,157]. Kim et
al [158] observed that p53 prevented EMT in primary hepatocellular carcinomas by repressing
ZEB1 and 2 in a 3′UTR-dependent manner. Furthermore, p53-induced ZEB1/2 repression was
mediated through up-regulation of various miRNAs; -141, -192, -193b, -194, -200b, -200c, -215,
-224, and -34a). p53 is able to positively modulate miRNA-205 expression in triple negative
breast cancer cell lines, through regulation of two newly identified target genes, E2F1 and
LAMC1, resulting in reduced cellular proliferation [159]. In addition, p53 knockdown can
increase proliferation of both luminal and basal-like breast cancer cell lines, in part through
up-regulation of miRNA-134,-146a, and-181b. Over-expression of miRNA-146a leads to
decreased NF-kB expression and inhibition of the NF-kB-dependent extrinsic apoptotic
pathway (TNF, FADD, and TRADD) in basal-like cells expressing mutant p53, suggesting that
targeting miR-146a expression may have potential therapeutic value for reducing the aggres‐
siveness of such tumors [160].
4. ER signalling, EMT and miRNA
Estrogen (E2), acting through ERα, plays a major role in controlling the normal growth and
development of mammary epithelial cells, as well as in the pathogenesis of breast cancer. E2
binding induces ERα activation by the dissociation of the inactive ER-heat shock protein
complex, leading to conformational changes, dimerization and autophosphorylation. The
activated dimer complex binds to either estrogen response elements (EREs) or to other
promoters such as the AP1/SP1 sites in target genes, to initiate events culminating in cellular
proliferation. Other target genes may include transcriptional repressors or initiate anti-
proliferative or pro-apoptotic function [161].
The mammary ducts are composed of an inner layer of luminal epithelial cells and an outer
layer of basal or myoepithelial cells. The majority of breast cancers arise from the luminal
epithelium of small mammary ducts, and are classified as luminal-A subtype, characterized
as low grade, weakly proliferative and invasive. These express ERα, PR, luminal associated
transcription factors such as GATA-3 and FOXA1, and epithelial markers such as E-cadherin
[162]. Luminal-A cancers can progress into more aggressive and metastatic forms through the
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EMT process. Although ERα plays a critical role in enhancing cellular proliferation, where
anti-estrogen therapy (e.g. tamoxifen) are the preferred treatment options, E2/ERα signaling
also promotes the differentiation of mammary epithelial cells along the luminal/epithelial
lineage and thereby opposes the EMT process. ERα stimulates the transcription factors required
for luminal differentiation such as GATA-3 and FOXA1 [163,164]. In fact, forced GATA-3
expression in mesenchymal-like breast cancer cells reduces their metastatic capabilities by
inducing MET [165]. ER signaling also suppresses EMT-promoting transcription factors such
as SLUG and SNAIL [166,167]. Furthermore, ER antagonizes signaling pathways that lead to
EMT, such as those of TGFβ and NFκB. E2/ERα signaling has been shown to oppose the action
of TGFβ in promoting EMT, by initiating formation of ternary complexes of Smad2/3 and
SmadE3 ubiquitin ligase smurf, thereby increasing the proteosomal degradation of Smad
proteins [168]. The NFκB subunit, RELB, is needed to maintain the mesenchymal phenotype;
ectopic expression of ERα in the presence of E2 was shown to decrease RELB expression in ER-
ve cell lines [169,170].
In our laboratory, we have established several endocrine resistant breast cancer cell lines that
exhibit an ERα-depleted phenotype induced by shRNA transfection of the ER+ve MCF-7 cells.
Such cells have all gained estrogen independence and exhibit a series of changes in morphol‐
ogy and enhanced motility and invasiveness accompanied by a modified gene expression
profile indicative of EMT. Microarray and real time-PCR analysis have confirmed the loss of
genes associated with epithelial cells such as E-cadherin, catenin, occludins, claudins, and
enhanced gene expression associated with mesenchymal cells such as N-cadherin, vimentin,
fibronectin, integrin β4 and α5, and various metalloproteinases [124,171,172]. This model of
endocrine resistance induced by ERα loss was also confirmed by others. Moreover, ectopic
ERα over-expression in ER–ve breast cancer cell lines reverses the EMT process through
enhanced E-cadherin and reduced SLUG expression [173].
The ERα mRNA has a long 3' UTR of about 4.3 kb which has been reported to reduce mRNA
stability and which bears evolutionarily conserved miRNA target sites, suggesting that it might
be regulated by miRNAs. Overall, ER–ve cells display generally lower levels of miRNA
expression. Of the miRNAs that are up-regulated there are distinct differences between ER-ve
and ER+ve cells (Figure 3).
Of note, miRNA-10b,-125, and-145 were significantly down-regulated in the majority of breast
cancer samples and cell lines, whereas miRNA-21,-17-5b,-29b-2,-146,-155, and 181b-1 were up-
regulated [126,174]. Estrogen has been shown to induce Dicer expression; loss of ERα may
contribute to reduced Dicer and consequently lower miRNAs levels in ER–ve cells. In addition,
some miRNA such as miRNA-29a, 103/107 and-200c, and let-7 inhibit Dicer expression and
thereby promote the EMT process [175,176,177,178]. Restoration of miRNA-200c in triple
negative breast cancer cells causes an increase in Dicer levels [176]. The expression of both
AGO-1 and-2 was reported to be significantly elevated in ER–ve cells [179]; forced expression
of AGO-2 enhanced breast cancer cell motility through reduced E-cadherin expression [180].
Understanding how miRNAs modulate ERα and its signaling pathway may offer new
therapeutic approaches to restore endocrine sensitivity and responsiveness to anti-estrogen
therapies, and reverse the EMT process, thereby reducing metastasis. The following section
A Concise Review of Molecular Pathology of Breast Cancer90
describes individual miRNAs that have been shown to modulate ERα expression and hence
the EMT process (Figure 4).
miRNA-22: over-expression of miRNA-22 represses ERα expression through the 3`UTR
leading to reduction in estrogen signaling. This also leads to impaired estrogen-induced
proliferation of MCF7 breast cancer cells to an extent similar to that of shRNA directed at the
ERα mRNA [181]. Similar findings were also reported by Xiong et al [182].
miRNA-145: transfection of miRNA-145 into ER+ve breast cancer cells significantly reduced
ERα protein levels through interaction of two miRNA-145 target sites within the coding region
of ERα mRNA, reducing the levels of its downstream target cyclin D1 [183].
miRNA-206: E2/ERα directly suppresses miRNA-206 levels [184], while the miRNA-206 itself
directly targets the mRNAs encoding components of ERα signaling molecules such as the
nuclear receptor co-activator proteins steroid receptor co-activator-1 (SRC-1) and-3 as well as
GATA-3 [184,185]. In addition, ectopic expression of miRNA-206 in ER+ve breast cancer cells
reduces endogenous ERα at both mRNA and protein levels and leads to enhanced invasive
capacity [186,187]. Moreover, miRNA-206 can also decrease the expression of DNA polymer‐
ase A1 subunits as well as the oncogenic receptor c-MET, while increasing the expression of
the tumor suppressor forkhead box O3 (FOXO3). Consequently, this leads to the inhibition of
cell proliferation, suggesting a role for miRNA-206 in repressing proliferation of ER+ve breast
cancer by enhancing myoepithelial differentiation and ERα silencing [30,184,188]. Enhanced
level/activity of EGF add its receptor (EGFR/HER1) is seen in mesenchymal type breast cancer
cells and may contribute to ER silencing though enhancement of miRNA-206 levels [184].
Ectopic expression of miRNA-206 in MCF-7 cells enhances IL-6 expression, which is known
Figure 3. Up-regulation of miRNA expression in relation to ER status of breast tumours
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to induce EMT through STAT signaling. Also, it maintains its level by autocrine positive
feedback loops that involve NFκB or NOTCH3 [189,190].
miRNA-221/222: expression of this pair of miRNAs was found to be higher in ER-ve compared
with ER+ve breast cancer cells. In this context, miRNA-221 and-222 can inhibit the translation
of the ERα mRNA [191]. Several studies have also suggested that ERα directly represses the
gene promoter region of both miRNAs by recruiting the co-repressors NCoR and SMRT [187].
Figure 4. miRNAs that negatively regulate ER expression in breast cancer. These act either directly (miRNA-22), or
through up-(blue) or down-(red) regulation of other target mRNAs.
5. miRNAs and cell invasion
Cancer cell invasion is a multi-step process which involves dissociation of extracellular matrix
components by the action of various proteases and the subsequent movement of detached
tumor cells from the original tumor site to distinct organs, and is associated with poor clinical
outcome and reduced survival rates. Several miRNAs have been implicated in either enhanc‐
ing or reducing cellular invasion by targeting various mRNAs that encode proteins crucial to
the process (Figure 5).
5.1. miRNAs with anti-metastatic actions
miRNA-7: expression of miRNA-7 was significantly reduced in cancer stem cells (CSCs)
isolated from breast cancer cell lines which demonstrated significant metastatic migration to
the bone and the brain. It attenuated the invasion and self-renewal of CSCs by enhancing the
expression of KLF4 [192]. A recent report also confirmed the anti-metastatic properties of
miRNA-7 both in vitro and in vivo by targeting the oncogene SETDB1 and showing decrease
in expression and activity of STAT3 in MDA-MB-231 cells [147].
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miRNA-18a: a recent report showed that over-expression of miRNA-18a in MDA-MB-231 cells
reduced cell invasiveness and sensitivity to anoikis and hypoxia in vitro, and primary tumor
growth and lung metastasis in vivo. On the other hand, its inhibition leads to a pro-metastatic
effect by targeting of the HIF1A gene [193].
miRNA-31: expression of miRNA-31 is reduced in several metastatic breast cancer cell lines,
and correlates inversely with metastasis in human breast cancer patients. Over-expression of
this miRNA in otherwise-aggressive breast tumor cells suppresses metastasis, whereas
inhibition of miRNA-31, by miRNA sponge strategy, induced metastasis in non-aggressive
breast cancer cells both in vitro and in vivo by enhancing the expression of several metastasis-
promoting genes including Fzd3, ITGA5, RDX, and RhoA [194].
miRNA-107: over-expression of this miRNA in MDA-MB-231 cells significantly inhibited cell
migration and invasion by targeting of the cyclin-dependent kinase 8 (CDK8) gene [195].
miRNA-124: expression of miRNA-124 was significantly reduced in MDA-MB-231 compared
to MCF-7 cells. Induced over-expression in MDA-MB-231 significantly inhibited cell migration
and invasion in vitro, in part through reduced SLUG and enhanced E-cadherin expression
[148,196]. In addition, reduced tumor formation and lung metastasis was seen in MDA-MB-231
cells over-expressing miRNA-124 when injected into the tail vein of nude mice [148]. Another
report confirmed its anti-metastatic role through its ectopic expression in MDA-MB-231 and
T47D cells, which significantly reduced their invasive capacity through targeting of flotillin-1
(FLOT1) [197]. Other evidence suggests that its anti-metastatic properties are exerted through
the suppression of several pro-metastatic genes such as connective tissue growth factor
(CTGF), Ras homolog family member G (RhoG), ITGB1 and ROCK1 [196].
miRNA-145: the expression of miRNA-145 was found to be reduced in breast cancer cells
compared to normal tissue, and its over-expression in various breast cancer cell lines (MDA-
MB-231, MCF-7, MDA-MB-468 and SK-BR-3) significantly reduced motility and invasiveness.
This effect was due to down-regulation of the cell–cell adhesion protein JAM-A and the actin
bundling protein fascin [198], and silencing of the metastasis gene mucin 1 (MUC1), with
subsequent reduction of beta-catenin as well as the oncogenic cadherin 11 [199].
miRNA-146a/b: over-expression of miRNA146a/b in MDA-MB-231 resulted in marked
inhibition of migration and invasion due to reduced NF-κB activity. This was through
miRNA146a/b-induced down-regulation of two key regulators of this signaling pathway;
interleukin (IL)-1 receptor-associated kinase and TNF receptor-associated factor 6 [200].
miRNA-149: a recent report [201], showed reduced expression of miRNA-149 in basal
compared with luminal A/B, erbB2/HER2 positive and normal-like cancers and cell lines. It
was also found to be inversely correlated with higher tumor stage. Over-expression of a mature
miRNA-149 mimic in MDA-MB-231 cells significantly reduced their spreading in culture; the
cells exhibited a depolarized actin cytoskeleton and failed to establish prominent cell protru‐
sions and lamellipodia. Moreover, significant reduction in migration and invasion towards a
serum plus EGF gradient was observed in cells over-expressing miRNA-149. These effects
were due to decreased phosphorylation levels of src and rac, and to targeting of the small
GTPases rap1a and rap1b, the downstream effectors of the integrin receptor.
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miRNA-195-5p: a recent study demonstrated that over-expression of miRNA-195-5p signifi‐
cantly inhibited MDA-MB-231 and MCF-7 breast cancer cell invasion by targeting cyclin E1
and raf-1/Ccdn1 genes respectively [202,203].
miRNA-223: over-expression of miRNA-223 in MDA-MB-231 significantly decreased cell
migration and invasion by down-regulating STAT5A [204].
Figure 5. miRNAs involved in breast cancer cell invasion. miRNAs can act as either inducers or inhibitors of invasion
by increasing (blue) or decreasing (red) the expression of various target genes as indicated.
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miRNA-302a: expression levels of this miRNA was significantly decreased in metastatic breast
cancer cell lines and tumor tissues, and enforced expression of miRNA302a significantly
inhibited both in vitro and in vivo cell invasion, by inhibiting the CXCR4 gene [205].
miRNA-335: the expression of miRNA-335 and-126 was lost in human breast cancer tissues
from patients who developed metastasis and relapse. Restoring miRNA-335 expression in
highly metastatic breast cancer cell lines suppresses lung and bone metastasis in vivo through
targeting of the progenitor cell transcription factor SOX4, the extracellular matrix component
tenascin C, the c-Mer tyrosine kinase MERTK, and the receptor protein tyrosine phosphatase
PTPRN2 [112].
5.2. miRNAs with pro-metastatic actions
miRNA-9: over-expression of miRNA-9 in human mammary epithelial cells and the human
breast cancer cell line SUM149 resulted in significant increase in their motility and invasiveness
in vitro, through E-cadherin suppression. In addition, it led to increased β-catenin activity as
well as vascular endothelial growth factor (VEGFA) expression in MCF7-RAS breast carcinoma
cells, with subsequent enhancement in their invasive capacity. Furthermore, miRNA-9
knockdown in the highly metastatic 4T1 mouse mammary tumour cells, inhibited lung
metastasis formation when injected into the mammary fat pads of syngeneic immunocompe‐
tent mice in vivo [128].
miRNA-10b: the transcription factor TWIST induces the expression of miRNA-10b [206],
which is highly expressed in metastatic breast cancer cells and correlates with poor clinical
progression in patients with breast cancer. Transfection of the antisense inhibitor for miR‐
NA-10b in MDA-MB-231 cells caused a significant reduction in the invasive properties of these
cells. Moreover, over-expression of this miRNA in otherwise non-metastatic breast tumour
cells (SUM149) initiates robust invasion and lung metastasis in vivo when injected into the
mammary fat pads of immunodeficient mice, by enhancing the expression of the pro-meta‐
static gene RHOC [113]. In addition, miRNA-10b also targets another pro-metastatic gene
which influences breast cancer cells; the guanidine exchanger factor for rac activation [T-
lymphoma invasion and metastasis (TIAM1)] [207]. Furthermore, Ahmad et al [208] demon‐
strated increased expression of miRNA-10b in the primary breast cancer specimens of patients
who subsequently developed brain metastasis compared to those who did not, suggesting that
miRNA-10b could serve as a prognostic factor for brain metastasis in breast cancer patients
and a potential target for anti-metastatic therapy.
miRNA-18b: expression of miRNA-18b was shown to be up-regulated in various breast cancer
cell lines and in clinical specimens of breast tumors. Inhibition of miRNA18b in breast cancer
cell lines significantly suppressed their invasive capacity by modulating several target genes
including NLRP7, KLK3, OLFM3, POSTN, MAGED4B, KIR3DL3, CRX, SEMG1, and CEA‐
CAM5 [209].
miRNA-21: suppression of the oncogenic miRNA-21 in MDA-MB-231 significantly reduced
invasion in vitro and lung metastasis in vivo through targeting of the tumour suppressor gene
tropomyosin 1 (TPM1), maspin, tissue inhibitor of metalloproteinase 3 (TIMP3), and the
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programmed cell death 4 (PDCD4) [92,210,211]. In addition, miRNA-21 is involved in HER2/
neu-induced cell invasion, which is mediated by the MAPK pathway [92].
miRNA-24: TGF-β treatment of breast cancer cell lines results in EMT and enhanced invasive
capacity. Down-regulation of miRNA-24 expression resulted in suppression of the TGF-β-
induced cell invasiveness through Net1A regulation [131].
Has-miRNA-30c:  enhanced expression of has-miRNA-30c was observed in MDA-MB-231
compared to the poorly metastatic MCF-7 cells. Transfection of has-miRNA-30c into MDA-
MB-231  cells  significantly  enhanced  their  invasive  capacity  towards  conditioned  osteo‐
blast  media,  while  transfection with anti-miRNA-30c had the opposite  effect.  This  effect
was due to targeting and inhibiting of NOV/CCN3, which has been described as an inhibitor
of invasion [212].
miRNA-221/222: up-regulation of miRNA-221/222 in breast cancer is associated with malig‐
nancy and poor clinical outcome, while down-regulation of this miRNA is inversely correlated
with metastasis [112,213,214,215]. Falkenberg et al [216] reported that miRN-221/222 is a
significant prognostic marker for distinguishing sub-groups, particularly in advanced nodal
(LN+) and HER2+breast tumors, and its over-expression in T47D, MDA-MB-231 and SKBR3
cell lines markedly enhanced their invasive capacity through targeting of the serine protease
urokinase-type plasminogen activator (uPA).
miRNA-301a: a study by Ma et al [217] demonstrated that miRNA-301a was significantly up-
regulated in primary tumor samples with a metastatic phenotype, as well as in metastatic
breast cancer cell lines. In vitro over-expression of miRNA-301a in the non-invasive MCF-7
cells leads to significant enhancement in migration and invasion through targeting of PTEN
and activation of the wnt/β-catenin signaling pathway, while its inhibition in the invasive
MDA-MB-231 significantly decreased cell invasion. Furthermore, mice injected with miR‐
NA-103a over-expressing MCF-7 cells displayed prominent lung metastasis, while mice
injected with MDA-MB-231 cells pre-treated with miRNA-103a inhibitor reduced the degree
of lung metastasis.
miRNA-373 and-520c: the expression of both these miRNAs (which are members of the same
family and share similar seed sequence [218]) was significantly up-regulated in clinical breast
cancer metastasis samples. Stable over-expression of miRNA-373 and-520c stimulated breast
cancer cell migration in vitro and in vivo by the suppression of the cell surface glycoprotein
CD44 through binding to the 3` UTR region of its mRNA [219]. In addition, miRNA-373
promotes cell invasion through targeting of sites in the promoter of E-cadherin mRNA [45].
miRNA-495: expression of miRNA-495 was significantly increased in both clinical breast
cancer tissue samples compared to adjacent normal breast tissue as well as in MDA-MB-231
compared to MCF-7. Over-expression of miRNA-495 significantly enhanced invasive capacity
of both cell lines, while its knockdown by miRNA-495 inhibitor showed the opposite effects.
Its pro-metastatic effect was due to targeting and inhibiting of the JAM-A gene [220].
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6. miRNAs implicated in breast cancer proliferation
Several miRNAs have been implicated in either enhancing or reducing cellular proliferation
by targeting various mRNAs that encode proteins crucial to the process (Figure 6).
miRNA-21: this was found to be highly expressed in breast tumors compared to normal breast
tissue biopsies. Suppression of miRNA-21 levels (using anti-miR-21 oligonucleotides) in
MCF-7 suppressed cell growth in vitro as well as the tumor growth in the xenograft mouse
model in vivo. This effect was associated with increased apoptosis, down-regulation of the anti-
apoptotic protein bcl-2 [221], and modulation of several survival-related genes including
ACTA2, APAF1, BTG2, FAS, p21, PDCD4, and SESN1 [211].
miRNA-22: it is highly expressed in ER-ve breast cancer cell lines and in clinical samples with
mesenchymal phenotype. miRNA-22-mediates growth repression of ER+ve breast cancer cells
and it might serve as a potential therapeutic agent in the treatment of ER+ve cancers [182].
miRNA-26a/b: a recent study by Tan et al [222] demonstrated that forced expression of
miRNA-26a/b markedly inhibited E2-stimulated proliferation of ER+ve breast cancer cells in
vitro by modulating CHD1, GREB1 and KPNA2 target genes. miRNA26a/b depletion enhanced
their proliferative capacity. In addition, injecting miRNA26a or by over-expressing MCF-7
breast cancer cells into nude mice, resulted in the formation of slower growing and signifi‐
cantly smaller tumors compared with tumors derived from untreated MCF-7 injected mice.
miRNA-27a: it has been suggested that miRNA-27a enhances the proliferation of breast cancer
cell lines through targeting of genes that regulate the specificity protein transcription factors
(Sp) which are often over-expressed in tumors and associated with enhanced proliferative and
angiogenic capacity. Suppression of miRNA-27a (using anti-sense miRNA-27a) in MDA-
MB-231 resulted in growth suppression through increased expression of Myt-1 and the zinc
finger ZBTB10 gene (a putative Sp repressor), and increased levels of Sp1, Sp3, and Sp4. In
addition, decreased expression of Sp-dependent survival and angiogenic genes, including
survivin, VEGF and VEGF receptor 1 (VEGFR1) was also seen after miRNA-27a suppression
[65].
miRNA-34c: the expression of miRNA-34c was significantly decreased in basal-like breast
cancer cells (MDA-MB-231, MDA-MB-468 and BT-549) and was associated with poor prog‐
nosis. Its over-expression resulted in suppressed proliferation and increased cell death by
influencing the cell cycle mainly by inducing an arrest in the G2/M phase and down-regulation
of various cell cycle-regulators such as CCND1, CDK4 and CDK6. Furthermore, CDC23 was
identified as an miRNA-34c-regulated target that could be responsible for the induction of cell
cycle arrest [223].
miRNA-93: this miRNA induced MET in claudin-low SUM159 cells, and reduced their
proliferation level through down-regulation of TGFβ signaling and multiple stem cell regu‐
latory genes such as JAK1, STAT3, AKT3, SOX4, EZH1, and HMGA2. On the other hand, it
enhanced the CSC population in MCF7 cultures that display a more differentiated phenotype,
suggesting different effects based on cellular differentiation state [224].
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miRNA-107: the expression of miRNA-107 was decreased in breast cancer specimens com‐
pared with adjacent normal tissues, and its over-expression significantly suppressed prolifer‐
ative capacity, and induced arrest at G0/G1 phase in MDA-MB-231 cells. These effects were
due to down-regulation of CDK8 target gene by miRNA-107 [195].
miRNA-124: expression of miRNA-124 was reduced in breast cancer tissues and inversely
correlated with TNM stage and lymph node metastasis. Its over-expression in MDA-MB-231
and T47D cells significantly inhibited their growth and proliferative capacity. This was due to
increased number of cells in the G0 and G1 phase and decreased number in the S, G2 and M
phases [197]. The anti-proliferative function of miRNA-124 in MDA-MB-231 and MCF-7 cells
was seen as a consequence of targeting and inhibiting the E26 transformation specific-1 (Ets-1)
gene [225].
miRNA-145: expression of this miRNA was significantly lower in breast cancer cell lines, as
well as in primary human breast tumors as compared with normal breast tissues. Transfection
with a synthetic miRNA-145 precursor into several breast cancer cell lines produced a pro-
apoptotic effect, which was dependent on p53-mediated transactivation of PUMA [183].
miRNA-195-5p: this miRNA was significantly down-regulated in breast cancer tissues
compared to adjacent normal tissues, and over-expression of miRNA-195-5p in MDA-MB-231
cells inhibited their proliferative capacity and ability to form colonies, and caused G1 phase
arrest by targeting of cyclin E1 (CCNE1) [202]. In addition, its over-expression also inhibited
the proliferative capacity of MCF-7 cells by targeting of raf-1 and Ccdn1 genes [203].
miRNA-196a: over-expression of miRNA196a in various breast cancer cell lines led to
reduction in their proliferative capacity by suppressing annexin A1 (ANXA1), a mediator of
apoptosis and inhibitor of cell proliferation [226].
miRNA-206: introduction of miRNA-206 into MCF-7 cells inhibited cell growth in a dose-and
time-dependent manner [188], in part through inducing a significant block in G1phase [191].
miRNA-221/222: by targeting the cell cycle inhibitor p27(Kip1) [216,227], miRNA-221/222
enhanced ER–ve breast cancer cell proliferation. In addition, it also increased ER+ve cell
proliferation by stimulating cell transition from G1 to S phase [191]. Other reports have
suggested that miRNA-221/222 is involved in the EGFR-RAS-RAF-MEK signaling pathway
and down-regulates PTEN, leading to enhanced cell proliferation [228,229].
miRNA-486-5p: expression of miRNA-486-5p was reduced in breast cancer biopsies compared
to adjacent non-neoplastic tissues, as well as in various breast cancer cell lines. Its over-
expression in MDA-MB-231 and T47D significantly reduced their proliferative capacity in
vitro by inducing G0/G1 arrest and promotion of apoptosis. Furthermore, its over-expression
in MDA-MB-231 cells significantly inhibited xenograft tumor growth when injected subcuta‐
neously into the right flank of nude mice. The oncogene PIM-1 was identified as a direct target
of miRN-486-5p, suggesting that the miRNA-486-5p/PIM-1 axis might be a useful therapeutic
target for prevention or treatment of breast cancer [230]. Zhao et al [231] demonstrated that
over-expression of miRNA-486-5p in SKBR3 cells inhibits HER3 expression and lowers its
downstream mediators, inhibits clonogenic potential, and enhances their sensitivity to
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trastuzumab or doxorubicin by repressing proliferative signal pathways mediated by HER3/
HER2/PI3K/AKT.
miRNA-769-3p: Luo et al (2014a) have shown that culturing MCF-7 cells under hypoxic
conditions followed by re-oxygenation enhanced the expression levels of various miRNAs
such as miRNA-769-3p,-501-3p,-2276, and-1282. Over-expression of miRNA-769-3p signifi‐
cantly inhibited cell proliferation and enhanced apoptosis by targeting and inhibiting the
expression of the NDRG1 gene, suggesting that miRNA-769-3p can functionally regulate
NDRG1 during changes in oxygen concentration in breast cancer cells.
Figure 6. miRNAs involved in breast cancer cell proliferation. miRNAs can act as either inducers or inhibitors of pro‐
liferation by increasing (blue) or decreasing (red) the expression of various target genes as indicated.
7. miRNAs controlling the biosynthesis of other miRNAs
An example of miRNAs regulating the expression levels of other miRNAs was reported by
Martello et al [139]. They showed that miRNA-103/107 attenuated the global biosynthesis of
other miRNAs through targeting of the RNase-III Dicer. miRNA103-107 also specifically
down-regulated miRNA-200, which led to EMT, and subsequent enhancement in breast cancer
cell invasion, but without major impact on primary tumor growth.
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8. miRNAs as therapeutic agents
Several studies, as outlined above, have highlighted the contribution of various miRNAs in
multiple processes of tumor pathogenesis (proliferation, invasion, EMT and endocrine/
chemotherapy resistance), making them potential tools for applications as indicators in breast
cancer diagnosis and staging, as markers of response to therapy and as therapeutic agents/
targets for treatment. Unlike mRNAs, miRNAs (presumably due to their smaller size) are
relatively stable in formalin fixed tissue specimens and in the blood stream, which facilitates
their detection/measurement. There is opportunity to develop miRNA-based drugs that target
specific oncomiRs or replace down-regulated miRNAs which have tumor suppressor proper‐
ties. Unlike other nucleic acid, protein or small molecule drugs, many miRNAs (such as
miRNA-31) have pleiotropic actions by which they can affect several related target genes; this
can have a desirable cumulative effect that has obvious advantages in treating multifactorial
diseases like cancer [194]. Of course it could also produce deleterious effects, so it is important
to identify all the potential targets of particular miRNAs.
The value of using miRNAs as diagnostic and/or prognostic signature in breast cancer is
currently receiving some attention. For example, miRNA-7,-128a, 210, and 516-3p can be used
as markers for distant metastases of ER+ve, lymph node-ve breast cancer cases [214], while
miRNA-210 can be used as marker for distant metastasis in triple –ve breast tumours
[214,232,233]. Some miRNAs could be used as markers for disease survival in ER+ve (e.g.
miRNA-128a,-135a, 767-3p) [234], ER–ve (e.g. miRNA-27b,-30c,-144,-150,-210,-342) [234], as
well as in triple negative breast tumours (e.g. miRNA-21,-205,-210,-221,-222) [235,236]. Also,
some miRNA such as-30a-3p,-30c, and-182 can be used as markers for response to adjuvant
tamoxifen treatment in advanced ER+ve cases [237], while miRNA-21can predict the response
to neoadjuvant trastuzumab treatment in breast cancer [213,238,239].
8.1. miRNA mimics
miRNA mimics, or replacement therapy, aims to restore normal levels of certain miRNAs that
are down-regulated. They usually carry the same sequence as the missing or deficient naturally
occurring miRNA. Introduction would be via viral or liposomal delivery [240].
8.2. Antagomirs
These are oligonucleotides that are chemically engineered to bind to a specific miRNA to
prevent it from interacting with its mRNA target. To increase their stability, they can be
chemically modified through the inclusion of 2’-O-methyl modified ribose sugars, 2’-O-methyl
ribose sugars with the addition of an extra 2’-O, 4’C methylene bridge sugar [241,242,243,244].
An example of an important miRNA in breast cancer pathogenesis is miRNA-21, which is
significantly up-regulated in breast tumors compared to normal tissue. Treatment of both ER
+ve and ER-ve breast cancer cells with anti-miRNA-21 oligonucleotides suppressed both cell
growth and migration in vitro and tumor growth in the xenograft mouse model in vivo
[213,221]. Furthermore, miRNA-21 has the capacity to sensitize breast cancer cells to some anti-
cancer agents such as topotecan and taxol [221]. Combination treatment of taxol with miR‐
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NA-21 inhibitor significantly decreased the 50% inhibitory concentration (IC50) of taxol in
breast cancer cells when compared with taxol monotherapy. In addition, treatment of the
miRNA-21 inhibitor-transfected cells with taxol resulted in significantly reduced cell viability
and invasiveness compared with control cells [213]. Of note, the most developed miRNA-based
agent to date is the miRNA-122 inhibitor for the treatment of hepatitis C virus [245], but before
reaching clinical usage its interaction with other clinically used drugs should be extensively
studied.
8.3. miR masks
Another range of compounds that are under development are known as target masks [246], of
which there are several types. A target mask is conceptually an oligonucleotide whose
sequence has been designed to bind either to an endogenous miRNA (miR sponge) or to its
target on the mRNA (sponge miR mask). Whilst the binding of the sponge miR mask will
prevent the binding of all miRNA belonging to the same seed family [247], (and is therefore
miRNA seed specific and not gene specific), the miR mask blocks only a particular miRNA
from interacting with its target mRNA.
These interactions are illustrated in Figure 7.
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Figure 7. Manipulation of miRNA function. Endogenous miRNAs bind to target sequences in the 3’ UTR regions of
their target mRNA, downstream of the open reading frame (ORF), to produce translational arrest. miRNA mimics are
synthetic oligonucleotide duplexes that have the same sequence as the endogenous miRNA and also produce the same
effect. Antagomirs (also called antimiRs) are oligonucleotides that have complementarity with the miRNA and bind to
it, preventing it from interacting with its target mRNA, thereby allowing normal mRNA translation. An miR mask is a
construct that is complementary to a sequence in the mRNA; this binding does not initiate mRNA degradation or
translational inhibition but prevents the endogenous miRNA from binding. The sponge miR mask differs from the
miR mask in that it binds to any mRNA with a similar target sequence and is therefore miRNA seed specific and not
gene specific.
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9. Summary
• miRNAs are endogenously synthesized single stranded RNA molecules that are 19-25
nucleotides in length, which play a vital role in the regulation of gene expression.
• Their exact mechanism of regulating gene expression is determined by the degree of
complementarity with their target mRNAs; perfect complementarity usually results in
mRNA degradation while permitted imperfect complementarity results in translational
inhibition.
• miRNA biogenesis takes place in two phases; nuclear and cytoplasmic, both of which
include events mainly carried out by Drosha, Argonaute and Dicer.
• The expression level of miRNA is mostly found to be down-regulated in cancers, and
miRNA-155 was the first to be found to actually induce tumorigenesis.
• miRNAs are differently expressed in ER-ve vs ER+ve breast cancer cells; enhanced expres‐
sion of miRNA-206,-221/222,-22, 150, and-29a was seen in ER-ve cells while enhanced
expression of miRNA-200c,-130a-26a,-142-5b,-201,-205,-25,-21 and let-7 family was seen in
ER+ve cells.
• miRNA-221/222 targets and down-regulates ERα, induces EMT, and enhances breast cancer
cell invasion and proliferation.
• miRNA-9,-24, and-155 induce EMT and enhance cell invasion.
• miRNA-7 and-44 inhibit EMT and decrease cell invasion.
• miRNA-124 and-145 inhibit EMT, and decrease cell invasion and proliferation.
• miRNAs could be used as non-invasive biomarkers for the diagnosis and prognosis, and as
a promising therapeutic target for breast cancer.
• miRNA mimicks, antagomiRs and miR masks are being developed as new ways to interfere
with miRNA regulation of gene translation in cancer cells.
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